FY2030 Earnings Estimate for TCRX Issued By HC Wainwright

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of TScan Therapeutics in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.09) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. The firm had revenue of $2.57 million for the quarter.

A number of other research analysts have also recently issued reports on TCRX. Wedbush lifted their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd. Finally, Morgan Stanley downgraded TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $6.20.

TScan Therapeutics Stock Up 6.0%

Shares of NASDAQ TCRX traded up $0.07 during mid-day trading on Thursday, hitting $1.15. 381,579 shares of the stock traded hands, compared to its average volume of 489,636. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The company has a market cap of $64.98 million, a price-to-earnings ratio of -1.02 and a beta of 1.03. The stock has a fifty day moving average price of $1.06 and a 200-day moving average price of $1.40. TScan Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.57.

Insider Activity

In other news, major shareholder Lynx1 Capital Management Lp bought 75,500 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $67,950.00. Following the transaction, the insider owned 8,012,916 shares of the company’s stock, valued at $7,211,624.40. The trade was a 0.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders purchased 161,801 shares of company stock worth $145,621. 4.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TCRX. BVF Inc. IL lifted its position in TScan Therapeutics by 6.9% in the second quarter. BVF Inc. IL now owns 5,226,074 shares of the company’s stock worth $7,578,000 after buying an additional 336,600 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of TScan Therapeutics by 7.8% in the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock valued at $4,219,000 after acquiring an additional 168,540 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of TScan Therapeutics by 31.8% in the 4th quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock valued at $1,785,000 after purchasing an additional 430,421 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after buying an additional 311,150 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of TScan Therapeutics by 14.9% during the 3rd quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock worth $763,000 after purchasing an additional 54,370 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.